Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Drugs · 2024
DOI: 10.1007/s40265-024-02029-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Luděk Horváth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Hauptthemen laut MEDLINE: Bariatric Surgery, Obesity, Anti-Obesity Agents, Weight Loss. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A global obesity pandemic is one of the most significant health threats worldwide owing to its close association with numerous comorbidities such as type 2 diabetes mellitus, arterial hypertension, dyslipidemia, heart failure, cancer and many others. Obesity and its comorbidities lead to a higher rate of cardiovascular complications, heart failure and increased cardiovascular and overall mortality. Bariatric surgery is at present the most potent therapy for obesity, inducing a significant weight loss in the majority of patients. In the long-term, a substantial proportion of patients after bariatric surgery experience a gradual weight regain that may, in some, reach up to a presurgical body weight. As a result, anti-obesity pharmacotherapy may be needed in some patients after bariatric surgery to prevent the weight regain or to further potentiate weight loss. This article provides an overview of the use of anti-obesity medications as an augmentation to bariatric surgery for obesity. Despite relatively limited published data, it can be concluded that anti-obesity medication can serve as an effective adjunct therapy to bariatric surgery to help boost post-bariatric weight loss or prevent weight regain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne and University of Manchester, Manchester, United Kingdom. Edward.jude@tgh.nhs.uk.
- Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. halm@ikem.cz.
Zitieren
APA
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024). Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity. Drugs. https://doi.org/10.1007/s40265-024-02029-0
Vancouver
Horváth L, Mráz M, Jude EB, Haluzík M. Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity. Drugs. 2024. doi:10.1007/s40265-024-02029-0
BibTeX
@article{Horvth2024,
author = {Horváth, Luděk and Mráz, Miloš and Jude, Edward B and Haluzík, Martin},
title = {Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity},
journal = {Drugs},
year = {2024},
doi = {10.1007/s40265-024-02029-0}
}
EUVIMED